David Griffin, MD
Gynecologic Oncology · Anderson, SCNPI 1508823618
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $579 and has fallen 76.4% since, to $137 in 2025.
Across 86 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Octapharma USA, Inc.$231
- Merck$230
- AstraZeneca$130
- Taiho Oncology, Inc.$120
- Eisai Inc.$104
- GSK$95
- plus $758 from 28 others
Across 27 payments — averaging $1805.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$20K
- Seagen Inc.$16K
- Genentech, Inc.$9K
- Genmab U.S., Inc.$3K
What the payments were for
- Food & beverage$1,65699%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Octapharma USA, Inc. | 1 | $231 |
| Merck | 14 | $230 |
| AstraZeneca | 7 | $130 |
| Taiho Oncology, Inc. | 6 | $120 |
| Eisai Inc. | 6 | $104 |
| GSK | 6 | $95 |
| Sun Pharmaceutical Industries Inc. | 1 | $66 |
| Genentech USA, Inc. | 5 | $65 |
| Clovis Oncology, Inc. | 5 | $58 |
| Novartis | 3 | $53 |
| AbbVie | 2 | $47 |
| Genmab U.S., Inc. | 2 | $39 |
| Karyopharm Therapeutics Inc. | 2 | $34 |
| Seagen Inc. | 2 | $32 |
| Puma Biotechnology, Inc. | 2 | $28 |
| Amgen | 2 | $27 |
| Bayer | 2 | $26 |
| Sanofi | 1 | $25 |
| Gilead | 1 | $24 |
| Daiichi Sankyo Inc. | 2 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Heron Therapeutics, Inc. | 1 | $19 |
| G1 Therapeutics, Inc. | 1 | $18 |
| Springworks Therapeutics, Inc. | 1 | $17 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Array Biopharma Inc | 1 | $15 |
| Pfizer | 1 | $14 |
| Incyte Corporation | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Dova Pharmaceuticals | 1 | $12 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
| Bristol Myers Squibb | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANZYGA$231
How this compares
Too few gynecologic oncology providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 12 | $291,165 |
| Prochlorperazine Maleate | 67 | $962 |
| Ondansetron OdtOndansetron | 67 | $839 |
| Dexamethasone | 41 | $434 |
| Letrozole | 19 | $381 |
| Sodium Chloride0.9 % Sodium Chloride | 38 | $184 |
| Ondansetron Hcl | 42 | $170 |
| Estradiol | 14 | $166 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $158 |
| Oxycodone Hcl | 31 | $155 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $143 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $101 |
| Tramadol Hcl | 25 | $54 |
| Ibuprofen | 25 | $53 |
| Metoclopramide Hcl | 19 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $104 | $291,16512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecologic oncology providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Other gynecologic oncology in Anderson
- Whitney GraybillCharleston$81K
- William MerrittColumbia$9K
- Mark MillerWest Columbia$8K
- James WilliamsColumbia$8K
- Courtney BaileyCharleston$5K
- Jonathan FooteCharleston$3K
- Catherine WatsonCharleston$3K
- Brian OrrCharleston$3K
- Larry PulsGreenville$2K
- Jeffrey ElderGreenville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.